Advancing excellence in laboratory medicine for better healthcare worldwide

Apolipoproteins by Mass Spectrometry (WG-APO MS)

Membership

Name Position Country Term Time in Office  
L.R. Ruhaak Chair NL 1st 2023 01 - 2025 12  
I. Begcevic Member        
U. Ceglarek Member DE      
V. Delatour Member FR      
J. Dittrich Member DE      
A. Hoofnagle Member US      
Z. Kuklenyik Member / CDC  US      
A. Lyle Member / CDC US      
H.W. Vesper Member / CDC US      
H. Althaus IVD Representative/Siemens DE      
U. Prinzing IVD Representative/Roche DE      
C. Cobbaert Consultant / Past Chair NL      
E. Angles-Cano Consultant FR      
G.M. Kostner Consultant AT      
F. Kronenberg Consultant AT      
L. Deprez Consultant / JRC BE      
I. Dikaios Consultant / JRC BE      

_________________________________________________________________________________________________

May 2021

Update on Reference Materials for Apolipoproteins    and

Infographic explaining the transitioning to a new RMS for apolipoproteins

_________________________________________________________________________________________________

April 2021

The AACC podcast on the SI-traceable RMS for standardization of serum apolipoproteins is available at following link:
https://podcasts.apple.com/us/podcast/towards-si-traceable-reference-measurement-system-for/id499883130?i=1000514846446
The associated Journal article is also available for download: https://academic.oup.com/clinchem/article/67/3/478/6040690

 

_________________________________________________________________________________________________
 

Terms of Reference

  • To achieve standardization of a panel of clinically relevant serum apolipoproteins (apo) A-I, B, C-I, C-II , C-III, E and apo (a) (including qualitative phenotyping where needed). Standardization is done in such a way that measurement results are traceable to SI as outlined in ISO 17511. Other traceability chains will be used in cases where traceability to SI cannot be achieved. 
  • To evaluate clinical performance and clinical utility of serum apolipoprotein panel(s) for CVD risk stratification and treatment, in comparison to or together with contemporary blood lipids.


 

Current projects

  • Define the analytes / measurands intended to be measured. 
  • Development of primary and secondary reference materials, including evaluation of commutability.
  • Development of an LC-MS/MS-based reference method for the above mentioned analytes that are unaffected by genetic variants, post-translational modifications and other factors. The reference method will meet relevant ISO standards (i.e., ISO 15195). 
  • Evaluation of the analytical performance of the LC-MS/MS reference method.
  • Assessment of the performance of commercially available apolipoprotein assays compared to the reference method using commutable reference materials as well as single donation samples. 
  • Any reference materials and reference measurement procedures developed will be submitted to JCTLM for review and listing on the JCTLM database.


 

Future Projects

  • Evaluation of clinical performance and clinical utility of the multiplexed apolipoprotein test according to the Test Evaluation framework developed by the EFLM working group on Test Evaluation (Horvath AR et al., CCA, 2014).


 

List of Corresponding Members, nominated by National Societies

Name Full and Affiliate Member Societies
Sang-Guk Lee Korean Society of Clinical Chemistry (KSCC)
Huseyin Kayadibi Turkish Biochemical Society (TBS)


 

List of Corresponding Members, nominated by Corporate Members

Name Corporate Members
Matthias Grimmler DiaSys
Zechen Liu MINDRAY
Xiaopeng Wang SNIBE


 

 

Working Group Chair's contact

Dr. Lucia Renee RUHAAK
Assistant Professor
Department of Clinical Chemistry and Laboratory Medicine
Leiden University Medical Center
Albinusdreef 2
2333 ZA, Leiden
The Netherlands
E-mail: l.r.ruhaak@lumc.nl

 
Website developed by Insoft